Vandetanib in thyroid cancer: Added benefit not proven
Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute ...
Aug 2, 2013
0
0